Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618709 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Safety and Pharmacokinetic Study of ATX-101
A Phase 1 study, sponsored by Kythera Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00618709 is a Phase 1 study that has completed, run by Kythera Biopharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT00618709, a Phase 1 study, has completed, sponsored by Kythera Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this research is to evaluate the safety and pharmacokinetic profile of single doses of ATX-101
Interventions
- DRUG ATX-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618709
The ClinicalTrials.gov registry entry for NCT00618709 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kythera Biopharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATX-101 is the first listed.
NCT00618709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00618709 about?
NCT00618709 is a clinical study titled "Dose-Escalation Safety and Pharmacokinetic Study of ATX-101". The purpose of this research is to evaluate the safety and pharmacokinetic profile of single doses of ATX-101
What is the current status of trial NCT00618709?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-01. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00618709?
The interventions under investigation include: ATX-101 (DRUG).
Who is sponsoring clinical trial NCT00618709?
This trial is sponsored by Kythera Biopharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.